The "Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis, 2024-2030" report has been added to ...

Morgan Stanley analyst Michael Ulz reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target ...

Analyst Gena Wang of Barclays maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...

On Thursday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $122.41 which represents a slight increase of $4.42 or 3.75% from the prior close of $117.99. The stock opened ...

We recently published a list of the 7 Best Revenue Growth Stocks to Buy According to Analysts. In this article, we are going ...

Since the FDA cleared Sarepta Thereapeutics' gene therapy for nearly all people with Duchenne, its stock price has tanked.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $177.83, a high ...

As of the latest trading close, SRPT, a Healthcare sector stock, is trading -30.90% below its 52-week high but remains 116.69% above its 52-week low. The Average True Range (ATR) (14 days) of 3.67 ...

Sarepta dominates the Duchenne muscular dystrophy market. Find out why recent insider buying of SRPT stock may signal ...

Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Sarepta Therapeutics (NASDAQ:SRPT) in the last three months. The table below provides a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sarepta Therapeutics (NASDAQ:SRPT) has emerged as a leader in the treatment of Duchenne muscular dystrophy (DMD) following the recent label expansion for its gene therapy Elevidys. This ...